Michael Burkes Brophy Sells 37,175 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 37,175 shares of the stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $242.54, for a total value of $9,016,424.50. Following the sale, the chief financial officer owned 64,123 shares in the company, valued at approximately $15,552,392.42. This trade represents a 36.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, January 20th, Michael Burkes Brophy sold 23,948 shares of Natera stock. The shares were sold at an average price of $234.74, for a total transaction of $5,621,553.52.
• On Wednesday, October 29th, Michael Burkes Brophy sold 1,867 shares of Natera stock. The shares were sold at an average price of $190.64, for a total transaction of $355,924.88.
• On Tuesday, October 28th, Michael Burkes Brophy sold 2,415 shares of Natera stock. The stock was sold at an average price of $191.16, for a total transaction of $461,651.40.
• On Monday, October 27th, Michael Burkes Brophy sold 781 shares of Natera stock. The shares were sold at an average price of $192.32, for a total transaction of $150,201.92.
• On Friday, October 24th, Michael Burkes Brophy sold 755 shares of Natera stock. The shares were sold at an average price of $196.77, for a total transaction of $148,561.35.

Natera Stock Performance

Shares of NASDAQ NTRA opened at $241.58 on Friday. The firm has a market cap of $33.42 billion, a P/E ratio of -105.49 and a beta of 1.62. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $256.36. The firm’s 50 day moving average price is $234.18 and its 200 day moving average price is $191.17.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The business had revenue of $592.18 million for the quarter, compared to analysts’ expectations of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The company’s revenue for the quarter was up 34.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.26) EPS. As a group, equities analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Zacks Research raised shares of Natera from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Evercore ISI increased their price target on shares of Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. JPMorgan Chase & Co. lifted their price target on shares of Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Morgan Stanley upped their price objective on Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a report on Monday, December 1st. Finally, BTIG Research lifted their target price on Natera from $230.00 to $260.00 and gave the company a “buy” rating in a report on Friday, December 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $245.50.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Peer‑reviewed clinical validation: Natera published clinical validation of its Latitude™ tissue‑free MRD test in colorectal cancer, boosting the credibility of a higher‑value oncology product that could support future revenue and reimbursement expansion. Clinical validation article
• Positive Sentiment: Analyst support: Multiple sell‑side firms have raised price targets and the consensus remains a “Moderate Buy” with an implied target around the mid‑$200s, providing medium‑term bullish backing for the stock.
• Neutral Sentiment: Fund positioning note: A Voya MidCap Opportunities investor letter and related coverage highlight that lack of exposure to Natera hurt that fund’s Q4 performance — a sign NTRA was a notable outperformer for some mid‑cap portfolios but not a direct company catalyst. Voya fund note
• Neutral Sentiment: Mixed fundamentals & ownership: Recent quarter showed strong revenue growth (~35% YoY) but continued GAAP losses; institutional ownership is extremely high (~99.9%), which reduces free float and can both support and cap volatility depending on flows.
• Negative Sentiment: Clustered insider selling — material: CEO Steven Chapman, CFO Michael Burkes Brophy and other insiders executed large sales on Jan. 20–21 (CEO sale ~71.9k shares; CFO sales totaling ~61k+ shares across days), representing sizable reductions in holdings and increasing perceived near‑term supply pressure. CEO Form 4
• Negative Sentiment: Additional insider sales: Multiple smaller insider transactions (e.g., Solomon Moshkevich) were also reported, reinforcing the market perception of insider liquidity taking and adding downward pressure. InsiderTrades coverage

Hedge Funds Weigh In On Natera

A number of institutional investors have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC increased its position in shares of Natera by 168.4% during the fourth quarter. Farther Finance Advisors LLC now owns 2,373 shares of the medical research company’s stock worth $544,000 after acquiring an additional 1,489 shares during the last quarter. Octavia Wealth Advisors LLC acquired a new stake in Natera during the 4th quarter valued at approximately $1,042,000. Assetmark Inc. increased its holdings in Natera by 4.4% during the 4th quarter. Assetmark Inc. now owns 17,401 shares of the medical research company’s stock worth $3,986,000 after purchasing an additional 737 shares during the last quarter. Transcend Capital Advisors LLC increased its holdings in Natera by 27.2% during the 4th quarter. Transcend Capital Advisors LLC now owns 2,381 shares of the medical research company’s stock worth $545,000 after purchasing an additional 509 shares during the last quarter. Finally, Choreo LLC raised its position in shares of Natera by 18.8% in the 4th quarter. Choreo LLC now owns 2,211 shares of the medical research company’s stock valued at $508,000 after purchasing an additional 350 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.